Amedisys Inc (NASDAQ:AMED)‘s stock had its “buy” rating restated by SunTrust Banks, Inc. in a research report issued on Friday. They presently have a $70.00 price target on the health services provider’s stock. SunTrust Banks, Inc.’s target price points to a potential upside of 24.44% from the stock’s previous close. SunTrust Banks also issued estimates for Amedisys’ FY2017 earnings at $2.23 EPS, Q1 2018 earnings at $0.59 EPS and Q3 2018 earnings at $0.67 EPS.
AMED has been the topic of several other reports. Mizuho lowered Amedisys from a “buy” rating to a “neutral” rating and set a $50.00 target price on the stock. in a report on Wednesday, July 26th. Benchmark Co. reaffirmed a “hold” rating on shares of Amedisys in a report on Thursday. Robert W. Baird reaffirmed a “hold” rating and set a $50.00 target price on shares of Amedisys in a report on Wednesday, October 4th. Bank of America Corporation began coverage on Amedisys in a report on Monday, August 21st. They set a “neutral” rating and a $55.00 target price on the stock. Finally, BidaskClub raised Amedisys from a “sell” rating to a “hold” rating in a report on Friday, August 11th. Six investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Amedisys presently has an average rating of “Hold” and a consensus price target of $61.00.
Amedisys (NASDAQ:AMED) opened at $56.25 on Friday. Amedisys has a 12 month low of $38.00 and a 12 month high of $65.91. The stock has a market capitalization of $1,913.69, a PE ratio of 26.98, a PEG ratio of 1.37 and a beta of 0.68. The company has a quick ratio of 1.21, a current ratio of 1.33 and a debt-to-equity ratio of 0.16.
ILLEGAL ACTIVITY NOTICE: This article was reported by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark laws. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3026658/amedisys-inc-amed-stock-rating-reaffirmed-by-suntrust-banks-inc-2.html.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN grew its holdings in Amedisys by 29.7% in the third quarter. Wells Fargo & Company MN now owns 1,484,041 shares of the health services provider’s stock valued at $83,048,000 after purchasing an additional 339,825 shares during the period. Virginia Retirement Systems ET AL acquired a new stake in Amedisys in the third quarter valued at approximately $1,802,000. Legal & General Group Plc grew its holdings in Amedisys by 7.6% in the third quarter. Legal & General Group Plc now owns 59,025 shares of the health services provider’s stock valued at $3,303,000 after purchasing an additional 4,166 shares during the period. FNY Managed Accounts LLC acquired a new stake in Amedisys in the third quarter valued at approximately $900,000. Finally, NorthCoast Asset Management LLC acquired a new stake in Amedisys in the third quarter valued at approximately $262,000. 96.36% of the stock is currently owned by institutional investors.
Amedisys Company Profile
Amedisys, Inc is a healthcare services company. The Company’s segments are Home Health, Hospice, Personal Care and Other. The Company is a provider of home health, hospice and personal care services. As of December 31, 2016, the Company owned and operated 327 Medicare-certified home healthcare centers, 79 Medicare-certified hospice care centers and 14 personal-care care centers in 34 states within the United States and the District of Columbia.
Receive News & Ratings for Amedisys Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys Inc and related companies with MarketBeat.com's FREE daily email newsletter.